PROX1 and colorectal carcinoma: By calculating the IRS, we found that PROX1 immunostaining was high in 58.1% (n = 126) and low in 41.9% (n = 91) of CRC samples, whereas in normal colorectal epithelial samples, PROX1 immunostaining was low in 68.3% (n = 148) and high in 31.7% (n = 69) (Figure 1B).